AMI Asset Management Corp Boosts Stock Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

AMI Asset Management Corp grew its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 50.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 77,688 shares of the company's stock after buying an additional 26,010 shares during the period. AMI Asset Management Corp owned 0.11% of Kiniksa Pharmaceuticals International worth $1,725,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its position in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after purchasing an additional 568 shares during the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $41,000. Wealthquest Corp purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $42,000. Lazard Asset Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $61,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $158,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Price Performance

KNSA traded down $0.45 during trading on Friday, reaching $28.04. 8,681,337 shares of the company's stock were exchanged, compared to its average volume of 552,513. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.38 and a 1 year high of $30.69. The stock has a market capitalization of $2.05 billion, a P/E ratio of -112.16 and a beta of 0.06. The company's fifty day simple moving average is $26.79 and its 200-day simple moving average is $22.63.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. The company had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. During the same period last year, the firm posted ($0.25) EPS. Kiniksa Pharmaceuticals International's revenue for the quarter was up 72.5% compared to the same quarter last year. Equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on KNSA shares. Jefferies Financial Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Wedbush reaffirmed an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, April 16th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Finally, Citigroup began coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $38.80.

Insider Activity

In other news, COO Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the completion of the transaction, the chief operating officer now directly owns 72,363 shares of the company's stock, valued at $2,207,795.13. The trade was a 38.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sanj K. Patel sold 2,872 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $27.03, for a total transaction of $77,630.16. Following the transaction, the chief executive officer now directly owns 96,674 shares of the company's stock, valued at approximately $2,613,098.22. This trade represents a 2.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 440,863 shares of company stock valued at $12,101,029 in the last three months. 53.48% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.